Citations

Clear

3 citation(s) found for "Shukla, Richa".

A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn’s disease
Johnson, Amanda M. , Askar, Manar, Belani, Seema, Xu, Anthony , Kassmeyer, Blake , Said, Hyder , Santiago-Castro, Michael, Devi, Jalpa , Huang, Katherine , Jaiprada, Fnu, Seth, Nickhil, Dulaney, David , Fenster, Marc, Shukla, Richa, Yarur, Andrés , Santiago-Castro, Michael , Devi, Jalpa , Bishu, Shrinivas , Ungaro, Ryan , Deepak, Parakkal , Yarur, Andres J , Khan, Abdul Wali , Seth, Nickhil, Loftus, Edward V. , Patel, Anish A , Bishu, Shrinivas , Ungaro, Ryan C. , Shukla, Richa, Deepak, Parakkal

Mayo Clinic

Journal of Crohn's and Colitis | April 18, 2025 | Volume: 19 | Issue: 5 | Pages: No page available

10.1093/ecco-jcc/jjaf070 | PMID 40289770 Get It

Abstract Background We aimed to evaluate the effectiveness and safety of risankizumab (RZB) for Crohn’s disease (CD) in routine clinical practice. Methods We performed a retrospective review of a multicenter consortium of CD patients treated with RZB. Co-primary outcomes were week 12 clinical remission (Harvey Bradshaw Index [HBI] score of ≤4 or physician global assessment in those without HBI or with ileostomy) and 6-month endoscopic remission (Simplified Endoscopic Mucosal Assessment for Crohn’s Disease of 0-1 or absence of ulcers). Secondary outcomes included steroid-free clinical remission, clinical response, radiographic response, cumulative clinical and endoscopic remission rates at 6 and 12 months, and adverse events. Results A total of 309 patients were included (median disease duration 14 years [IQR, 6-24]; median follow-up 7.1 months [IQR, 4.1-10.3]). Most patients (85.8%) were advanced therapy (AT)-exposed, and 169 (54.7%) had prior ustekinumab (UST) exposure. Week 12 clinical remission rates were 49.7% (98/197) overall, and 44.2% (50/113) vs 57.1% (48/84) in UST-exposed vs naïve patients (P = .073). Among those with active disease on baseline endoscopy (n = 122) who had an available follow-up at 6 months, 52.4% (22/42) achieved endoscopic remission. Cumulative rates of clinical and endoscopic remission at 12 months were 65.0% and 49.5%, respectively. Cumulative 12-month endoscopic remission was 33.9% (19/56) in UST-exposed and 68.1% (32/47) in UST-naïve patients (P < .001). Risankizumab was well-tolerated with no new safety signals identified. Conclusions In this large multicenter cohort of patients with CD, RZB was well-tolerated and effective in achieving favorable clinical and endoscopic outcomes in both AT-exposed and naïve populations, including those with exposure to UST.
S1288 Real-World Effectiveness of Ozanimod for Ulcerative Colitis in Patients With Prior Advanced Therapy Exposure: A Multicenter Study
Scalzo, Nicholas , Lieto, Stephen, Huang, Katherine , Xu, Anthony , Rajauria, Palak , Ayoub, Malek , Johnson, Amanda M. , Yarur, Andrés , Dulaney, David , Seth, Nikhil , Shukla, Richa, Sokol, Uyen, Sands, Bruce E., Yarur, Andres J , Khan, Abdul Wali , Pekow, Joel , Patel, Anish A , Bishu, Shrinivas , Shukla, Richa, Jain, Anjali , Rubin, David T. , Sands, Bruce E , Deepak, Parakkal , Ungaro, Ryan C.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S921-S921

10.14309/01.ajg.0001034520.61834.16 Get It

Factors Associated With Extraintestinal Manifestations of Inflammatory Bowel Disease in SPARC-IBD
Alizadeh, Madeline , Motwani, Kiran , Abutaleb, Ameer, Ravel, Jacques , Investigators, SPARC-IBD, Bewtra, Meena, Lewis, James D. , Wong, Uni , Korzenik, Josh, Duerr, Rick, Saha, Sumona , Raffals, Laura E. , Shukla, Richa, Dassopoulos, Themistocles , Bohm, Matthew , Beniwal‐Patel, Poonam , Brook, Lauren, Ciorba, Matthew A. , Deepak, Parakkal , Ravel, Jacques , Deepak, Parakkal , Siaton, Bernadette C. , Cross, Raymond K. , Investigators, SPARC-IBD, Russ, Kirk , Lewis, James D , Snapper, Scott B. , Bishu, Shrinivas , Duerr, Rick, Caldera, Freddy , Shukla, Richa, Hudesman, David , Pekow, Joel , Scoville, Elizabeth

Mayo Clinic

Inflammatory Bowel Diseases | December 16, 2023 | Volume: 30 | Issue: 11 | Pages: 2027-2036

10.1093/ibd/izad280 | PMID 38102817 Get It

Abstract Background Extraintestinal manifestations (EIMs) of inflammatory bowel diseases (IBDs) are a common and debilitating feature of disease, occurring in up to 40% of patients with IBD, yet predicting who may develop them is difficult. The goal of our study was to better characterize which patients may be at highest risk of developing not only 1 EIM, but also multiple EIMs, across both diseases. Methods A retrospective study of participants enrolled in the SPARC IBD (Study of Prospective Adult Research Cohort with IBD) registry was performed, and demographic and clinical data were analyzed. A total of 1211 patients with data available on EIMs were included, and differences among variables with vs without EIMs were assessed. Results A total of 329 participants with at least 1 EIM were identified, compared with 882 participants without any EIMs. Crohn’s disease patients and women were more likely to have 2 or more EIMs (P = .005 and P ≤ .001, respectively). Participants with ocular manifestations were likeliest to have at least 2 EIMs (P ≤ .001). Even when diagnosis was controlled for, involvement of the right colon (P = .021) was predictive of IBD-associated arthritis across both diseases in a multivariate generalized linear model. Conclusions This is the first comprehensive large-cohort assessment of how EIMs relate to one another at the individual vs systems levels. Further, our analysis is the first to recognize specific locations of colon involvement associated with EIMs of IBD, regardless of IBD type. These results are important in identifying patients at risk of developing future EIMs and may help with risk stratification when choosing treatments.